Sort
15,273 grants matching “antimicrobial resistance”
Development of peptide nucleic acid antibiotics
$998,585Dev Priya Arya · Nubad, Llc · R42 · FY2024 · AI
VTEU: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI)
$998,309Mark Joseph Mulligan · Emory University · N01 · FY2018 · AI
Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing
$998,154Paul Rhodes · Specific Diagnostics, Inc. · R44 · FY2022 · AI
Preventing outbreaks of foodborne pathogenic bacteria in edible sprouts via novel resistance-conferring seed treatments
$998,060Murli Manohar · Ascribe Bioscience Inc. · R44 · FY2022 · AI
An automated platform for direct-from-specimen identification of pathogens common in endocarditis
$998,005Alon Singer · Helixbind, Inc. · R44 · FY2020 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis
$997,875Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R44 · FY2023 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE EMERGENCE OF ANTIMICROBIAL RESISTANCE (AMR) HAS INCREASED THE PRESSURE TO FIND ALTERNATIVE MEANS TO ELIMINATE OR REDUCE THE USE OF MEDICALLY-IMPORTANT ANTIMICROBIALS, PARTICULARLY IN THE AGRICULTURAL INDUSTRY. BOVINE RESPIRATORY DISEASE COMPLEX IS ONE OF THE COSTLIEST ISSUES ASSOCIATED WITH FEEDLOT CATTLE AND IS FREQUENTLY COMBATTED THOUGH METAPHYLACTIC ADMINISTRATION OF ANTIMICROBIALS UPON FEEDLOT ARRIVAL. THEREFORE, RESEARCH IS NEEDED TO DETERMINE THE EMERGENCE, ECOLOGY, AND MICROBIOME OF AMR AND DEVELOP SCIENCE-BASED STRATEGIES TO REDUCE THE INCIDENCE OF AMR THROUGHOUT THE BEEF PRODUCTION CONTINUUM. THESE STUDIES WILL PURSE THE FOLLOWING OBJECTIVES 1) IDENTIFY A BEST MANAGEMENT PRACTICE FOR METAPHYLACTIC ANTIMICROBIAL USE IN HIGH-RISK CATTLE, 2) IMPLEMENT NOVEL SCIENCE-BASED INTERVENTION STRATEGY TO REDUCE THE SPREAD OF AMR IN THE BEEF CATTLE INDUSTRY, 3) DEVELOP SYSTEMS BASED APPROACHES TO IDENTIFY AMR RESERVOIRS BY EVALUATING THE HOST-MICROBIOME COMMUNITY DYNAMICS, AND 4) IMPROVE UNDERSTANDING AMONG CURRENT AND FUTURE VETERINARIANS AND NUTRITIONISTS OF POTENTIAL FOOD SAFETY RISKS ASSOCIATED WITH CARRIAGE OF AMR BY BEEF CATTLE AND MOTIVATE THEM TO ADVISE PRODUCERS OF BEST PRACTICES FOR ANTIMICROBIAL STEWARDSHIP. COMPLETION OF THIS RESEARCH WILL IDENTIFY CRITICAL CONTROL POINTS FOR CONTROLLING THE DEVELOPMENT OF AMR AND PROVIDE USABLE SCIENCE-BASED APPROACHES TO MITIGATE AMR IN BEEF PRODUCTION. THIS INFORMATION IS CRITICAL FOR SUSTAINABILITY IN THE BEEF FOOD SUPPLY AND JUDICIOUS USE OF ANTIMICROBIALS IN CATTLE PRODUCTION.
$997,829Texas Tech University System · · FY2020 · National Institute of Food and Agriculture
RFA-GH-20-005, Project of Febrile Illness Surveillance in the Andean and Amazon Countries (PISAAC)
$997,603Eduardo Gotuzzo · Universidad Peruana Cayetano Heredia · U01 · FY2023 · GH
Development of RSK Inhibitors as Novel Therapeutics for Yersinia pestis
$997,346Michael J Danilich · Luna Innovations, Inc. · R44 · FY2010 · AI
Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis
$997,234Alon Singer · Helixbind, Inc. · SB1 · FY2024 · AI
An Integrated Diagnostic System for Rapid Antimicrobial Susceptibility Testing
$997,129Vincent Jen-Jr Gau · Genefluidics, Inc. · R44 · FY2012 · AI
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides
$996,973Jian Li · Monash University · R01 · FY2016 · AI
Preclinical development of teixobactin, a new antibiotic
$996,881Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2019 · AI
Optimizing Inhibitors of T. gondii ENR
$996,821Rima L McLeod · University Of Chicago · U01 · FY2009 · AI
Multiplexed Assay for Point-of-Care UTI Diagnosis (ID/AMR)
$996,726Alison Burklund · Nanopathdx, Inc. · R44 · FY2024 · AI
Diagnostic tool for assessment and tracking of microbial load in bloodstream infections
$996,497Alon Singer · Helixbind, Inc. · R44 · FY2025 · AI
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
$996,458Justin Blaine Schaal · University Of Southern California · R01 · FY2024 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** ANTIBIOTIC RESISTANCE HAS BEEN WIDELY IDENTIFIED AS A GLOBAL HEALTH ISSUE OF CRITICAL FUTURE SIGNIFICANCE. HOWEVER, QUESTIONS REMAIN OVER THE SPREAD OF ANTIBIOTIC RESISTANCE IN AGRICULTURAL SYSTEMS WHERE ANTIBIOTICS AND ANTIBIOTIC RESISTANCE DETERMINANDS (ARDS), E.G., ANTIBIOTIC RESISTANCE GENES (ARGS), ANTIBIOTIC RESISTANT BACTERIA (ARB), AND MOBILE GENETIC ELEMENTS (MGES), CAN BE APPLIED TO SOILS IN WASTEWATER AND MANURE.USING A SERIES OF GREENHOUSE AND OUTDOOR (LARGER-SCALE) EXPERIMENTS, WE WILL QUANTIFY THE MOVEMENT OF ANTIBIOTICS AND ARDSBETWEEN WASTEWATER/MANURE, SOIL, PLANTS, AND ANIMALS (EARTHWORMS). UNDERSTANDING THESE PATHWAYS IS OF CRITICAL IMPORTANCE IN ASSESSING THE POTENTIAL FOR ANTIMICROBIAL RESISTANCE TO SPREAD THROUGH FOOD CHAINS. ONCE THESE PATHWAYS ARE MORE CLEARLY UNDERSTOOD, THE USE OF BIOCHAR APPLICATION TO SOIL AS A STRATEGY FOR REDUCING THE SPREAD OF ANTIBIOTIC COMPOUNDS AND ANTIBIOTIC RESISTANCE WITHIN THE AGRICULTURAL SYSTEM WILL BE ASSESSED.THE RESEARCH RESULTS WILL BE THEN BE USED IN NUMERICAL MODELS TOQUANTIFYTHE POTENTIAL RISKS OF ANTIMICROBIAL RESISTANCE WITHIN ANIMAL AND HUMANFOOD CHAINS. THIS WORK WILL HELP PROTECT HUMAN HEALTH FROM THE POTENTIAL RISKS OF ANTIBIOTIC RESISTANCE.
$996,446Regents Of The University Of California At Riverside · · FY2021 · National Institute of Food and Agriculture
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic
$996,046Michael Lafleur · Arietis · R44 · FY2022 · AI
Lab-on-a-Film Multiplexed Test for Respiratory Mycobacterial Infections
$996,031Christopher Gerard Cooney · Akonni Biosystems, Inc. · R44 · FY2024 · AI
Direct from blood identification of bloodstream infections in newborns
$995,893Alon Singer · Helixbind, Inc. · R44 · FY2024 · AI
Therapeutic phage host-range prediction using proximity-guided metagenomics and artificial intelligence
$995,873Ivan Liachko · Phase Genomics, Inc. · R44 · FY2023 · AI
Therapeutic phage host-range prediction using proximity-guided metagenomics and artificial intelligence
$995,873Ivan Liachko · Phase Genomics, Inc. · R44 · FY2022 · AI
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic
$995,100Michael Lafleur · Arietis · R44 · FY2023 · AI
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic
$995,100Michael Lafleur · Arietis · R44 · FY2021 · AI